Increasing occurrence of the
disease especially in the Africa region will drive the sickle cell anemia
therapeutics market
There is a growing need of early
detection and prevention of curable diseases especially among the adults. This
is going to be a key opportunity in the Sickle
Cell Anemia Therapeutics Market as the percentage of adult population is
increasing on a daily basis owing to the rise in life expectancy among the
global population. Additionally, the demand for safe and efficacious treatments
is gaining prevalence in the market. This factor coupled with unmet medical
needs among the patients will fuel the growth of the global sickle cell anemia
therapeutics industry.
According to the World Health
Organization, around 5% of the population around the globe carries the gene for
the sickle cell disease. This percentage is as high as 25% in some of the
regions around the world. According to the same report, WHO has estimated that
the occurrence of sickle cell disease is highest in the African region. To meet
this crisis of high prevalence of the disease, WHO’s governing bodies has taken
initiatives to address the same. Moreover, according to PLOS Medicine, the
occurrence of sickle cell anemia is likely to rise by around 30% by 2050,
especially in the sub-Saharan Africa. This rise in demand will eventually push
the global sickle cell anemia therapeutics market into a positive growth
trajectory over the course of the forecast period (2016-2024).
Manufacturers around the world are
competing on the availability of technologically advanced drugs for the
treatment of sickle cell anemia. Key players operating in the global sickle
cell anemia therapeutics market are Bristol-Myers Squibb, GlycoMimetics,
Pfizer,Anthera Pharmaceuticals Inc., GlycoMimetics, Inc., Eli Lilly, and Mast
Therapeutics.Some of the other manufacturers are Daiichi Sankyo, Novartis
Pharmaceuticals, Bluebird Bio, HemaQuest Pharmaceuticals Inc., Emmaus Medical,
HemaQuest Pharmaceuticals, Baxter, and Merck Sharp & Dohme.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/161
A drastic reduction in the total
red blood cells or RBC count or hemoglobin is known as anemia. It can be
defined as the inability to carry optimum amount of oxygen by the blood.
Sickle-cell diseases (SCD) are types of blood disorders which are usually
inherited genetically. One of the common types of SCDs is the sickle-cell
anemia or SCA. It essentially gives rise to an irregularity in hemoglobin, the
protein that carries oxygen in the blood. Hemoglobin is found typically in the
red blood cells of the body. As a result a sickle-like shaped cell is formed
under certain conditions. Tribulations in sickle cell disease usually start to
take shape at a very early age (within the first year of birth). This might
lead to various health problems including pain attacks also known as the
sickle-cell crisis, swelling in the limbs, microbial infections, and in certain
cases, stroke. Chronic pain may develop with age. Sickle-cell diseases arise
when an individual inherits abnormal copies of hemoglobin gene from each
parent.
According to Center for Disease
Control and Prevention, as of 2016, around 100,000 people in the U.S. are
affected by sickle cell diseases or SCDs. Sickle cell diseases are very common
among black or African Americans. Around 1 in 13 babies belonging to the race
are born with sickle cell diseases. Growing prevalence of the disease will give
rise to an increased demand for sickle cell disease prevention and cure,
thereby augmenting the growth of the overall sickle cell anemia therapeutics
market.
The National Center for
Biotechnology Information says that sickle cell anemia is one of the most
common hereditary hematological diseases among humans. Annually, around 250,000
children are born with the disease and it is among the most occurring
epidemiological genetic diseases worldwide. Governments around the world,
especially in Africa are taking initiatives to prevent and cure the disease as
a result of which, huge investments on this field are expected in the coming
years. This in turn will encourage the manufacturers around the world to
manufacture in large quantities to meet the unmet demand thereby propelling the
growth of the sickle cell anemia therapeutics market.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/sickle-cell-anemia-therapeutics-market-161
Key Developments
Research and development of novel
technologies that may aid in treatment of sickle cell anemia is expected to
boost the market growth. For instance, in July 2019, researchers from Florida
Atlantic University, in a study published in the journal ACS Sensors,
demonstrated a microfluidic impedance assay that can monitor the dynamic cell
sickling and unsickling processes. The novel technology is expected to improve
the monitoring of sickle cell disease.
Key players in the market are
focused on launching platform to screen drugs to treat sickle cell disease. For
instance, in August 2019, ReachBio Research Labs started offering a drug
screening platform to assess fetal hemoglobin protein induction in drug
candidates for the treatment of sickle cell disease.
However, failing clinical trials
for the treatment of sickle cell anemia are expected to hinder the market
growth. For instance, in August 2019, Pfizer Inc. announced that the Phase III
Rivipansel pivotal study, to evaluate the efficacy and safety of rivipansel in
patients aged six and older with sickle cell disease, failed to achieve its primary or key
secondary efficacy endpoints.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/161
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment